IP Library Granted Patent US 7,071,336
Granted Patent B2
US 7,071,336 · App. 10/892,578 · Granted Jul 4, 2006

Process for manufacturing opioid analgesics

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,071,336
App. No.
10/892,578
Granted
Jul 4, 2006
Kind
B2
Abstract

Oxycodone is manufactured in high yields and with a high purity using a composition including a thebaine component into 14-hydroxycodeinone and then reduction of 14-hydroxycodeinone to oxycodone.

Claims (27)

1. A process for the preparation of oxycodone, which comprises the steps of:

(a) oxidation of a composition including a thebaine component into 14-hydroxycodeinone; and

(b) reduction of 14-hydroxycodeinone to oxycodone;

wherein the composition including a thebaine component comprises a concentrate of poppy straw.

2. For the preparation of an oxycodone acid salt, which comprises the steps of:

a) oxidation of a composition including a thebaine component into 14-hydroxycodeinone;

b) reduction of 14-hydroxycodeinone to oxycodone;

c)transformation of the oxycodone to an acid salt.

3. The process of claim 1 , wherein step (a) is carried out by reacting the thebaine component with an oxidizing agent in the presence of a solvent.

4. The process of claim 3 , wherein the oxidizing agent comprises a peracid.

5. The process of claim 3 , wherein the oxidizing agent of step (a) comprises hydrogen peroxide in combination with one or more of formic acid, peracetic acid, 3-chloroperoxybenzoic acid, and potassium peroxymonosulfate.

6. The process of claim 3 , wherein the solvent of step (a) is selected from the group consisting of formic acid and water, formic acid and methanol and water, formic acid and isopropanol, formic acid and water and isopropanol and formic acid and water and aqueous mineral acid, acetic acid and water and aqueous mineral acid.

7. The process of claim 3 , wherein the solvent comprises formic acid and water and isopropanol.

8. The process of claim 3 , wherein the solvent comprises formic acid and water and aqueous sulfuric acid.

9. The process of claim 3 , wherein the solvent comprises acetic acid and water and aqueous sulfuric acid.

10. The process of claim 1 , wherein step (b) is carried out by reacting the 14-hydroxycodeinone intermediate in the presence of a hydrogenation solvent.

11. The process of claim 10 , wherein step (b) is carried out in the presence of a heterogeneous catalyst, hydrogen gas, and a deactivating agent.

12. The process of claim 11 , wherein the heterogeneous catalyst of step (b) comprises a noble metal catalyst selected from the group consisting of platinum on carbon, palladium on carbon, palladium on barium sulfate, ruthenium on carbon, and chlorotris(triphenylphosphine)rhodium.

13. The process of claim 11 , wherein the deactivating agent of step (b) is selected from the group consisting of thiourea and pyridine.

14. The process of claim 10 , wherein the hydrogenation solvent of step (b) is selected from the group consisting of ethyl acetate and chloroform; dioxane and chloroform; methanol and chloroform; and aqueous phosphate buffer and tetrahydrofuran.

15. The process of claim 2 , wherein the oxycodone is isolated in the form of its hydrochloride salt by reacting the oxycodone with hydrochloric acid or hydrogen chloride gas in the presence of a solvent selected from the group consisting of a C1–C4 alcohol, acetone and mixtures thereof with water.

16. The process of claim 1 , wherein the concentrate of poppy straw comprises a concentrate of poppy straw having a thebaine content of about 30 to 83 wt.%.

17. The process of claim 2 , wherein the acid salt is selected from the group consisting of phosphate, hydrochloride, sulfate and acetate.

18. The process of claim 1 , wherein the 14-hydroxycodeinone or its salt produced in step (a) is utilized in step (b) without isolation or purification.

19. The process of claim 2 , wherein the oxycodone produced in step (b) is transformed to the salt in step (c), without isolation or purification.

20. The process of claim 2 , wherein the oxycodone salt is manufactured without isolating or purifying any of the intermediates produced in the course of steps (a) and (b).

21. The process of claim 1 , wherein a thebaine salt is isolated from the concentrated poppy straw by reacting concentrated poppy straw with an acid in the presence of a solvent selected from the group consisting of an alcohol, a ketone and mixtures thereof, before step (a), wherein the thebaine salt is oxidized in step (a).

Assignments (11)
SECURITY INTEREST Recorded Jul 2, 2019
From: SCHUTTE, JOHN
To: ABUSE DETERRENT PHARMACEUTICALS, LLC
Reel/Frame 049650/0104 →
SECURITY INTEREST Recorded Jul 2, 2019
From: ACURA PHARMACEUTICALS, INC.
To: SCHUTTE, JOHN
Reel/Frame 049649/0950 →
RELEASE OF SECURITY INTEREST Recorded Oct 11, 2018
From: OXFORD FINANCE LLC
To: ACURA PHARMACEUTICALS, INC.; ACURA PHARMACEUTICALS TECHNOLOGIES, INC.
Reel/Frame 047140/0800 →
SECURITY INTEREST Recorded Mar 17, 2017
From: ACURA PHARMACEUTICALS, INC.; ACURA PHARMACEUTICAL TECHNOLOGIES, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 041623/0740 →
CHANGE OF NAME Recorded Jul 1, 2015
From: HALSEY DRUG CO., INC.
To: ACURA PHARMACEUTICALS, INC.
Reel/Frame 036052/0786 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2015
From: LIN, ZHAIWEI; FRANCIS, CHARLES AUXILIUM; KALDAHL, CHRISTOPHER ARNE; ANTCZAK, KAZIMIERZ GRZEGORZ; KUMAR, VIJAI
To: HALSEY DRUG COMPANY, INC.
Reel/Frame 035993/0357 →
RELEASE OF SECURITY INTEREST Recorded Oct 10, 2007
From: GALEN PARTNERS III, L.P.
To: ACURA PHARMACEUTICALS, INC.
Reel/Frame 019930/0568 →
SECURITY AGREEMENT Recorded Jan 31, 2006
From: ACURA PHARMACEUTICALS, INC.
To: GALEN PARTNERS III, L.P.
Reel/Frame 017097/0150 →
SECURITY AGREEMENT Recorded Nov 11, 2005
From: ACURA PHARMACEUTICALS, INC.
To: GALEN PARTNERS III, L.P.
Reel/Frame 016769/0109 →
SECURITY INTEREST Recorded Sep 19, 2005
From: ACURA PHARMACEUTICALS, INC.
To: GALEN PARTNERS III, L.P.
Reel/Frame 016814/0160 →
SECURITY INTEREST Recorded Jun 22, 2005
From: ACURA PHARMACEUTICALS, INC.
To: GALEN PARTNERS III, L.P.
Reel/Frame 016408/0558 →